NO20002440D0 - Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet - Google Patents

Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet

Info

Publication number
NO20002440D0
NO20002440D0 NO20002440A NO20002440A NO20002440D0 NO 20002440 D0 NO20002440 D0 NO 20002440D0 NO 20002440 A NO20002440 A NO 20002440A NO 20002440 A NO20002440 A NO 20002440A NO 20002440 D0 NO20002440 D0 NO 20002440D0
Authority
NO
Norway
Prior art keywords
mmp
inhibitory activity
hydroxamic
carboxylic acid
acid derivatives
Prior art date
Application number
NO20002440A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002440L (no
Inventor
Andrew Douglas Baxter
David Alan Owen
John Gary Montana
Robert John Watson
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9723906.5A external-priority patent/GB9723906D0/en
Priority claimed from GBGB9802618.0A external-priority patent/GB9802618D0/en
Priority claimed from GBGB9813933.0A external-priority patent/GB9813933D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of NO20002440L publication Critical patent/NO20002440L/no
Publication of NO20002440D0 publication Critical patent/NO20002440D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
NO20002440A 1997-11-12 2000-05-11 Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet NO20002440D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9723906.5A GB9723906D0 (en) 1997-11-12 1997-11-12 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activiy
GBGB9802618.0A GB9802618D0 (en) 1998-02-06 1998-02-06 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GBGB9813933.0A GB9813933D0 (en) 1998-06-26 1998-06-26 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
PCT/GB1998/003395 WO1999024399A1 (en) 1997-11-12 1998-11-12 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (2)

Publication Number Publication Date
NO20002440L NO20002440L (no) 2000-05-11
NO20002440D0 true NO20002440D0 (no) 2000-05-11

Family

ID=27269088

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002440A NO20002440D0 (no) 1997-11-12 2000-05-11 Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet

Country Status (18)

Country Link
EP (1) EP1030836B1 (de)
JP (1) JP2001522832A (de)
KR (1) KR100609926B1 (de)
CN (1) CN1283183A (de)
AT (1) ATE231837T1 (de)
AU (1) AU748843B2 (de)
BR (1) BR9814147A (de)
CA (1) CA2308359A1 (de)
DE (1) DE69811111T2 (de)
DK (1) DK1030836T3 (de)
ES (1) ES2190115T3 (de)
HU (1) HUP0100152A3 (de)
IL (1) IL135921A (de)
NO (1) NO20002440D0 (de)
NZ (1) NZ504387A (de)
PL (1) PL340551A1 (de)
RU (1) RU2210567C2 (de)
WO (1) WO1999024399A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336840A (en) * 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6479502B1 (en) 1998-08-29 2002-11-12 British Biotech Pharmaceuticals Hydroxamic acid derivatives as proteinase inhibitors
EP1129086A1 (de) 1998-11-12 2001-09-05 Darwin Discovery Limited Hydroxamsäure und carbonsäure derivate mit mmp und tnf inhibitorischer wirkung
HRP20010660A2 (en) 1999-02-08 2005-02-28 G.D. Searle & Co Sulfamato hydroxamic acid metalloprotease inhibitor
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
EP1286994A1 (de) * 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
EP1282614B1 (de) * 2000-05-15 2003-11-12 Darwin Discovery Limited Hydroxamsäure derivate
JP2003533513A (ja) 2000-05-15 2003-11-11 ダーウィン・ディスカバリー・リミテッド Mmpおよびtnf阻害活性を有するヒドロキサム酸およびカルボン酸誘導体
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド (e)−n−ヒドロキシ−3−(3−スルファモイル−フェニル)アクリルアミド化合物及びその治療用途
EP1335898B1 (de) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
KR20030082990A (ko) * 2001-03-15 2003-10-23 아스트라제네카 아베 메탈로프로테이나제 억제제
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
GB0119396D0 (en) * 2001-08-09 2001-10-03 Celltech R&D Ltd Hydroxamic acid derivatives
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
NZ536116A (en) 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
WO2003091247A2 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0216382D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
GB0216383D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
EP1583736A1 (de) 2003-01-17 2005-10-12 TopoTarget UK Limited Carbaminsäureverbindungen die eine ester- oder keton-gruppe enthalten als hdac inhibitoren
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
RU2277418C1 (ru) * 2004-12-08 2006-06-10 Государственное научное учреждение (ГНУ) Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии (ВНИВИПФиТ) Препарат для лечения бронхопневмонии у телят
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
RU2286141C1 (ru) * 2005-03-03 2006-10-27 Общество с ограниченной ответственностью "Фарм-Лад" Мазь для наружного применения
EP2040698A4 (de) * 2006-07-14 2011-08-10 Shionogi & Co Oximverbindungen und ihre verwendung
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
EP2346820B1 (de) 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoylverbindungen und deren verwendung
KR20220164216A (ko) * 2021-06-04 2022-12-13 에스티팜 주식회사 신규한 에르고스텐올 유도체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1067965A (en) * 1965-01-22 1967-05-10 Beecham Group Ltd Penicillins, esters, amides and salts thereof
US5239079A (en) * 1988-05-12 1993-08-24 Eisai Co., Ltd. Pyridinium salt and pharmacological composition containing the same
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren

Also Published As

Publication number Publication date
EP1030836A1 (de) 2000-08-30
CN1283183A (zh) 2001-02-07
PL340551A1 (en) 2001-02-12
ATE231837T1 (de) 2003-02-15
DK1030836T3 (da) 2003-05-26
AU1046999A (en) 1999-05-31
AU748843B2 (en) 2002-06-13
CA2308359A1 (en) 1999-05-20
HUP0100152A3 (en) 2002-07-29
NZ504387A (en) 2002-10-25
KR20010032042A (ko) 2001-04-16
EP1030836B1 (de) 2003-01-29
KR100609926B1 (ko) 2006-08-04
ES2190115T3 (es) 2003-07-16
HUP0100152A2 (hu) 2002-02-28
IL135921A0 (en) 2001-05-20
DE69811111D1 (de) 2003-03-06
NO20002440L (no) 2000-05-11
JP2001522832A (ja) 2001-11-20
IL135921A (en) 2005-08-31
RU2210567C2 (ru) 2003-08-20
DE69811111T2 (de) 2003-07-24
BR9814147A (pt) 2000-10-03
WO1999024399A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
NO20002440L (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
FI971412A0 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
GB9801690D0 (en) Therapeutic agents
ATE233274T1 (de) Oxyiminopregnancarbolactone
DK0952148T3 (da) Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater
NO941662D0 (no) Benzofuranyl- og -tiofenyl-alkankarboksylsyrederivater
BR9808214A (pt) Compostos de n-hidróxi 4-sulfonil butanamida
ATE224374T1 (de) 1,2-substituierte imidazolylverbindungen zur behandlung von entzündungen
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
DE69432035D1 (de) Saccharinderivate als proteolytische Enzyminhibitoren
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
IT1285770B1 (it) Composti corticoidei
ID21698A (id) Karboksamida-karboksamida aril bisiklik dan penggunaan terapinya
NZ513096A (en) Compositions for treating inflammatory response
SE9904674D0 (sv) Novel compounds
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
DE60005517D1 (de) Kaliumkanal-blockierende mittel
EA200000205A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
EP1325918A4 (de) Herzmuskelzellen-apoptose hemmstoffe und behandlung/vorbeugung von herzkrankheiten
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
ATE31925T1 (de) 2-(formylamino)-n-(1h-tetrazol-5-yl)benzamide.
NO20075410L (no) Vetrinaerbruk av et pleuromutilinderivat
SU1607351A1 (ru) 3-БЕНЗОИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ХИНОКСАЛИН, ПРОЯВЛЯЮЩИЙ ПРОТИВОСТАФИЛОКОККОВУЮ АКТИВНОСТЬ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application